Graphic featuring a syringe to illustrate an HIV vaccine trial

Innovation-opedia: What is a mosaic vaccine?

As the IAS Conference on HIV Science kicks off in Mexico City, we explain how an investigational HIV vaccine from the Janssen Pharmaceutical Companies of Johnson & Johnson works—and how researchers hope to help change lives around the world with it.

Written by Johnson & Johnson

| July 22, 2019

July 22, 2019

Illustrated handwritten definition of a mosaic HIV vaccine

Illustration of a microscope with information about Janssen Vaccines & Prevention B.V. investigational HIV-1 vaccine regimen

Inset- Innovation-opedia: What Is a Mosaic Vaccine?- mosaic-vaccine-4-immunizations_above

Illustration of the # 4 explaining how many injections would be administered for Janssen’s investigational HIV-1 vaccine.

Inset- Innovation-opedia: What Is a Mosaic Vaccine?- mosaic-vaccine-4-immunizations_below

Illustration showing location of the IAS Conference on HIV Science with details about Janssen’s new Mosaico clinical trial.

Illustrated quote by Janssen’s Maria Grazia Pau talking about the goal of creating a global HIV vaccine.

We’re committed to helping lead the fight against HIV/AIDS

Read about the many ways Johnson & Johnson is working to #makeHIVhistory.

CTA-Red ribbon HIV

HIV vaccine J&J Innovative Medicine Johnson & Johnson

More from Johnson & Johnson

Innovation

September 14, 2026

Striving for a cure for multiple myeloma: What HCPs need to know

Jordan Schecter, M.D., leader of Johnson & Johnson’s end-to-end development strategy for multiple myeloma, shares insight on the evolving treatment landscape of this rare blood cancer.

Read more
Health & wellness

August 25, 2026

What is wAIHA?

Warm autoimmune hemolytic anemia (wAIHA) causes fatigue so profound, it can limit the lives of people who have the condition. Learn more about this rare disease and Johnson & Johnson’s clinical research and ongoing commitment to patients.

Read more
Innovation

August 21, 2026

Behind the relentless pursuit of multiple myeloma cures

For 25 years, Johnson & Johnson has pursued innovative blood cancer treatments. Scientist Kodandaram “Ram” Pillarisetti has helped shape that pursuit, from discovering a target that led to an approved bispecific therapy to research exploring a next-generation trispecific antibody approach.

Read more